After Sputnik V, Russian Federation approves second COVID-19 vaccine - EpiVacCorona

Johnson & Johnson pauses large, late-stage COVID-19 vaccine trial after testing subject contracts unexplained illness

"These ensure our studies may be paused if an unexpected serious adverse event (SAE) that might be related to a vaccine or study drug is reported, so there can be a careful review of all of the medical information before deciding whether to restart the study", the company added.

Russian President Vladimir Putin on Wednesday announced the country has registered the second vaccine against coronavirus (COVID-19) infection after "Sputnik V". Now, media reports say that Russian Federation has also approved its second Covid-19 vaccine.

At the same time, he stressed that Russian vaccines against coronavirus must first meet all the needs of the domestic market and reach as many pharmacies as possible.

Clinical trials of an experimental vaccine against COVID-19 which is being developed by France's Sanofi and USA biotech firm Translate Bio are on track to begin before the end of the year after positive results in tests on animals.

More than ten thousand Apollo employees are undergoing required training and will be stationed at Apollo centers to administer the vaccine. The BBIBP-CorV vaccine used in this study is based on a sample of the virus that was isolated from a patient in China. Also Read - Swine coronavirus: Are we staring at another pandemic similar to COVID-19? However, as the clinical trials are short, we will not know how long the vaccines will provide immunity. Deputy prime minister Tatiana Golikova said during the conference with Putin that the vaccine showed a "fairly high level of safety".

Last month, CNN reported that Russian teachers, meant to be among the first to received Sputnik V, were not eager to take the vaccine.

Sputnik V was developed by the Gamaleya National Research Institute of Epidemiology and Microbiology.

Bharat Biotech cut phase II trial size by half Bharat Biotech, the Indian pharmaceutical developing Covaxin, has made a decision to cut phase II clinical trials by half. "I may need to wait so my grandparents can get a vaccine'".

Throughout the clinical trial, participants did not report any side effects and after the first and second vaccinations, laboratory tests were performed to assess the function of different organs.

A division of Chinese state-run Sinopharm Group Co Ltd that is developing two COVID-19 vaccines is offering them for free to Chinese students going overseas for higher studies, the Wall Street Journal reported on Wednesday.